May 28, 2013 / 12:49 PM / in 4 years

Valeant eyeing merger but smaller buys more likely now -CEO

May 28 (Reuters) - Valeant Pharmaceuticals International Inc continues to have discussions about a potential “merger of equals,” but cannot predict the timing, Chief Executive Michael Pearson said on Tuesday.

Valeant, which has agreed to buy Bausch & Lomb for $8.7 billion, is not likely to make another major transaction in the near term, but is looking for smaller acquisitions, Pearson said on a conference call with analysts.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below